ASX · PTX.AX
Prescient Therapeutics Limited
A$0.05-A$0.00 (-3.64%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 57.6% below the high.
Loading market information…
ASX · AGN.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 01:24 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Argenica Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Argenica Therapeutics Ltd’s next earnings report is currently expected on Mar 2, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Argenica Therapeutics Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| A$1.40B |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.05-A$0.00 (-3.64%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 57.6% below the high.
A$0.02+A$0.00 (+6.25%)
AnteoTech Limited’s quoted price sits in the lower half of its reported 52-week range, 65.31% below the high.
A$0.15A$0.00 (0.0%)
Nova Eye Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 26.83% below the high.
A$0.04A$0.00 (0.0%)
Emyria Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
A$0.08+A$0.00 (+5.0%)
BCAL Diagnostics Limited’s quoted price sits in the lower half of its reported 52-week range, 45.81% below the high.
A$0.04A$0.00 (0.0%)
Microba Life Sciences Limited’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
A$0.14A$0.00 (0.0%)
INOVIQ Ltd’s quoted price sits in the lower half of its reported 52-week range, 76.11% below the high.
A$0.05A$0.00 (0.0%)
Noxopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 55.45% below the high.
